PERSBRA: Evaluation of the Feasibility of Developing Personalized Breast Cancer Radiotherapy Assistive Device With 3D Printing

Sponsor
Taipei Medical University Hospital (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04929197
Collaborator
(none)
50
1
1
72
0.7

Study Details

Study Description

Brief Summary

Breast cancer is the most common malignancy among women worldwide. For early stage breast cancer, adjuvant radiotherapy is essential to minimize loco-regional disease recurrence. However, significant portions of the heart and the lungs are exposed to low dose radiation during radiotherapy, which result in stochastic side effects among breast cancer survivors. Inspired by 3D printing technology, we approached this issue with an in-house made PERSonalized BReAst holder system (PERSBRA). PERSBRA is composed of a 3D-printed plastic holder covering the whole breast and an air-filled interface. Its main function is to reproducibly adjust the breast position to decrease heart and lung radiation exposure in tangential fields. Here we propose to measure the performance of PERSBR in terms of radiation dosimetry in 50 patients receiving scheduled whole breast irradiation. For customized PERSBRA, body shape of the patient with or without a bustier corset will be captured with a handheld 3D scanner and input into a 3D printer for PERSBRA design and manufacturing. A participant will receive two more CT scans in addition to the simulation scan with PERSBRA in place before the first and the sixth fractions of irradiation. These images will be analyzed for dosimetric parameters in the presence/absence of PERSBRA as well as position reproducibility. The data will provide proof-of-principle evidence for the clinical utility of PERSBRA and will facilitate its further refinement.

Condition or Disease Intervention/Treatment Phase
  • Device: PERSBRA
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of the Feasibility of Developing Personalized Breast Cancer Radiotherapy Assistive Device With Three-dimensional Printing Secondary IDs:
Actual Study Start Date :
Apr 21, 2016
Actual Primary Completion Date :
Apr 20, 2017
Anticipated Study Completion Date :
Apr 20, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Wear Personalized breast holder system (PERSBRA) to receiving radiotherapy

Wear PERSBRA to the end of radiotherapy.

Device: PERSBRA
After the patient is in the semi-prone position, the body shape and breast position images are obtained by the stereo scanning technology, and then using 3d printing technology to print PERSBRA. PERSBRA maintain a favorable new breast position in the supine position during routine radiotherapy, the cardiopulmonary dose during radiotherapy can be reduced by wearing PERSBRA.

Outcome Measures

Primary Outcome Measures

  1. Irradiated cardiac dose [Time Frame: At simulation, expected average of 1 week]

    Radiation dose distribution of the cardiopulmonary on the affected side.

Secondary Outcome Measures

  1. Irradiated dose of left anterior descending artery [Time Frame: At simulation, expected average of 1 week]

    Radiation dose distribution of the left anterior descending artery on the affected side.

  2. Irradiated lung dose [At simulation, expected average of 1 week]

    Radiation dose distribution of the lung on the affected side.

  3. Clinical target volume [At simulation, expected average of 1 week]

    Radiation dose distribution of clinical target volume.

  4. Irradiated dose of axillary lymphatic area [At simulation, expected average of 1 week]

    Irradiated dose of axillary lymphatic area.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with early breast cancer or carcinoma in situ after partial mastectomy have decided to receive adjuvant radiation therapy for the breast on the affected side, and use non-contrast computed tomography to obtain localized images is part of the original treatment plan.
Exclusion Criteria:
  • Clinical diagnosis or pathological diagnosis has lymph node metastasis, lymph node micrometastasis, or lymph node tumor cells.

  • The clinical diagnosis is likely to have metastatic cancer.

  • Pregnant women.

  • Be younger than 20 years old.

  • The subject was unable to read and understand the subject consent form written in Chinese and complete the informed consent procedure.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Taipei Medical University Hospital Taipei Taiwan

Sponsors and Collaborators

  • Taipei Medical University Hospital

Investigators

  • Study Director: Long-Sheng Lu, MD, Ph.D., Taipei Medical University Hospital
  • Study Chair: Jeng-Feng Chiou, MD, Ph.D., Taipei Medical University Hospital

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Taipei Medical University Hospital
ClinicalTrials.gov Identifier:
NCT04929197
Other Study ID Numbers:
  • N201603037
First Posted:
Jun 18, 2021
Last Update Posted:
Jun 18, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 18, 2021